Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors.

e13511 Background: Preclinical data show that the histone deacetylase inhibitor vorinostat (V) enhances chemotherapy at levels of > 2.5 μM. However the approved oral dose of V of 400 mg/d inconsist...